SEARCH

SEARCH BY CITATION

References

  • BALDWIN, H.A., COLADO, M.I., MURRAY, T.K., DE SOUZE, R.J. & GREEN, A.R. (1993). Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and the effect of the neuroprotective drugs chlormethiazole and dizocilpine. Br. J. Pharmacol., 108, 590596.
  • BALDWIN, H.A., WILLIAMS, J.L., SNARES, M., FERREIRA, T., CROSS, A.J. & GREEN, A.R. (1994). Attenuation by chlormethiazole administration of the rise in extracellular amino acids following focal ischaemia in the cerebral cortex of the rat. Br. J. Pharmacol., 112, 188194.
  • BARRETT, P.J. (1992). Ecstacy and dantrolene. Br. Med. J., 305, 1225.
  • BERGER, U.D., GUX, F. & AZMITIA, P. (1992). The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur. J. Pharmacol., 215, 153160.
  • BRONSTEIN, D.M. & HONG, J.S. (1995). Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality. J. Pharmacol. Exp. Ther., 274, 943950.
  • BROWN, C. & OSTERLOH, J. (1987). Multiple severe complications from recreational ingestion of MDMA (‘esctasy’). J. Am. Med. Assoc., 258, 780781.
  • CASHMAN, J.R., PROUDFOOT, J., PATE, D.W. & HOGBERG, T. (1988). Stereoselective N-oxygenation of zimeldine and homozimeldine by the flavin-containing monooxygenase. Drug Met. Dis., 16, 616622.
  • CLARK, W.G. & LIPTON, J.M. (1986). Changes in body temperature after administration of adrenergic and serotonergic agents and related drugs including antidepressants III. Neurosci. Biobehav. Rev., 10, 153220.
  • COLADO, M.I. & GREEN, A.R. (1994). A study of the mechanism of MDMA (‘Ecstasy’)-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds. Br. J. Pharmacol., 111, 131136.
  • COLADO, M.I., MURRAY, T.K. & GREEN, A.R. (1993). 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br. J. Pharmacol., 108, 583589.
  • COLADO, M.I., O'SHEA, E., GRANADOS, R., ESTEBAN, B., MARTIN, A.B. & GREEN, A.R. (1999). Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’) administration. Br. J. Pharmacol., 126, 911924.
  • COLADO, M.I., O'SHEA, E., GRANADOS, R., MURRAY, T.K. & GREEN, A.R. (1997). In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA (‘ecstasy’) and p-chloroamphetamine but not the degeneration following fenfluramine. Br. J. Pharmacol., 121, 889900.
  • COLADO, M.I., WILLIAMS, J.L. & GREEN, A.R. (1995). The hyperthermic and neurotoxic effects of Ecstasy (MDMA) and 3,4-methylenedioxymethamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP poor metabolizer phenotype. Br. J. Pharmacol., 115, 12811289.
  • CRESPI, D., MENNINI, T. & GOBBI, M. (1997). Carrier-dependent and Ca2+ dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylenedioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br. J. Pharmacol., 126, 911924.
  • CREWE, H.K., LENNARD, M.S., TUCKER, G.T., WOODS, F.R. & HADDOCK, R.E. (1992). The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br. J. Clin. Pharmacol., 34, 262265.
  • DAFTERS, R.I. (1994). Effects of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’) in rats. Psychopharmacology, 114, 505508.
  • DOWLING, G.P., MCDONOUGH, E.T. & BOST, R.O. (1987). Ecstasy, a report of five deaths associated with the use of MDEA and MDMA. J. Am. Med. Assoc., 257, 16151617.
  • FAUNT, J.E. & CROCKER, A.D. (1987). The effects of selective dopamine receptor agonists and antagonists on body temperature in rats. Eur. J. Pharmacol., 133, 243247.
  • GOODWIN, G.M. & GREEN, A.R. (1985). A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-Ht, and 5-HT2 receptors. Br. J. Pharamcol., 84, 743753.
  • GORDON, C.J., WILKINSON, W.P., O'CALLAGHAN, J.P. & MILLER, D.B. (1991). Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol. Biochem. Behav., 38, 339344.
  • GRAHAME-SMITH, D.G. (1971a). Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J. Neurochem., 18, 10531066.
  • GRAHAME-SMITH, D.G. (1971b). Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltyptamine in rats treated with a monoamine inhibitor. Br. J. Pharamcol., 43, 854864.
  • GRANT, R.T. (1963). Vasodilatation and body warming. J. Physiol., 167, 311317.
  • GREEN, A.R. & GRAHAME-SMITH, D.G. (1976). Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature, 260, 487491.
  • GUDELSKY, G.A., YAMAMOTO, B.K. & NASH, J.F. (1994). Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. Eur. J. Pharmacol., 264, 325330.
  • HENRY, J.A., JEFFREYS, K.J. & DAWLINGS, S. (1992). Toxicity and deaths from 3,4-methylenedioxymethamphetamine (‘ecstasy’). Lancet, 340, 384387.
  • HENRY, J.A. (1992). Ecstasy and the dance of death. Br. Med. J., 350, 56.
  • JOHNSON, M.P., HOFFMAN, A.J. & NICHOLS, D.E. (1986). Effects of the enantiomers of MDA, MDMA and related analogues on [3H]-serotonin and [3H]-dopamine release from superfused rat brain slices. Eur. J. Pharmacol., 132, 269276.
  • KOCH, S. & GALLOWAY, M.P. (1997). MDMA induced dopamine release in vivo: role of endogenous serotonin. J. Neural. Transm., 104, 135146.
  • KÖNIG, J.F.R. & KLIPPEL, R.A. (1963). A stereotaxic atlas of the forebrain and lower parts of the brain stem. The rat brain. Krieger Publishing, New York.
  • LIECHTI, M.E. & VOLLENWEIDER, F.X. (2000). The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers. J. Psychopharmacol., 14, 269274.
  • MALBERG, J.E., SABOL, K.F. & SEIDEN, L.S. (1996). Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produce different effects on body temperature in the rat. J. Pharmacol. Exp. Ther., 278, 258267.
  • MALLICK, A. & BODENHAM, A.R. (1997). MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C. Emergency Med. J., 14, 336338.
  • MAREK, G.J., VOSMER, G. & SEIDEN, L.S. (1990a). Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine. Brain Res., 513, 274279.
  • MAREK, G.J., VOSMER, G. & SEIDEN, L.S. (1990b). The effects of monoamine uptake inhibitors and methamphetamine on neostriatal 6-hydroxydopamine (6-OHDA) formation, short-term monoamine depletions and locomotor activity in the rat. Brain Res., 516, 17.
  • MCCALL, R.B. & SCHUETTE, M.R. (1984). Evidence for an alpha-1 receptor mediated central sympathoinhibitory action of ketanserin. J. Pharamcol. Exp. Ther., 228, 704710.
  • MCCANN, U.D. & RICAURTE, G.A. (2001). Caveat emptor: editors beware. Neuropsychopharmacology, 24, 333334.
  • MECHAN, A.O., COLADO, M.I., ESTABAN, B., ELLIOTT, J.M. & GREEN, A.R. (2000). Evidence against MDMA-induced hyperthermia being mediated by 5-HT release in the brain. Br. J. Pharmacol., 131, 155P.
  • MECHAN, A.O., O'SHEA, E., ELLIOTT, J.M., COLADO, M.I. & GREEN, A.R. (2001). A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long term defect in thermoregulation. Psychopharmacology, 155, 413418.
  • METZGER, R.R., HANSON, G.R., GIBB, J.W. & FLECKENSTEIN, A.E. (1998). 3,4-Methylenedioxymethamphetamine-induced acute change in dopamine transporter function. Eur. J. Pharmacol., 349, 205210.
  • MOHAGHEGH, R.A., SOULSBY, M.E., SKINNER, R.D. & KENNEDY, R.H. (1997). The interaction between the central and peripheral nervous systems in mediating the thermic effect of methamphetamine. Ann. N.Y. Acad. Sci., 813, 197213.
  • MORDENTI, J. & CHAPPELL, W. (1989). The use of interspecies scaling in toxicokinetics. In. Toxicokinetics and new drug development. eds Yacobi, A., Kelly, J. & Batra, V. pp. 4296. New York: Pergamon Press.
  • NAKACHI, N., KIUCHI, Y., INAGAKI, M., INAZU, M., YAMAZAKI, T. & OGUCHI, K. (1995). Effects of various dopamine uptake inhibitors on striatal extracellular dopamine levels and behaviours in rats. Eur. J. Pharmacol., 281, 195203.
  • NASH, J.F. (1990). Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci., 47, 24012408.
  • NASH, J.F. & BRODKIN, J. (1991). Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: Effect of dopamine uptake inhibitors. J. Pharmacol. Exp. Ther., 259, 820825.
  • NASH, J.F., MELTZER, H.Y. & GUDELSKY, G.A. (1988). Elevation of serum prolactin and corticosterone concentrations after administration of 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther., 245, 873879.
  • O'SHEA, E., GRANADOS, R., ESTEBAN, B., COLADO, M.I. & GREEN, A.R. (1998). The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (‘ecstasy’). Neuropharmacology, 37, 919926.
  • O'SHEA, E., ESTEBAN, B., CAMARERO, J., GREEN, A.R. & COLADO, M.I. (2001). Effect of GBR12909 and fluoxetine on the acute and long term change induced by MDMA (‘ecstasy’) on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology, 40, 6574.
  • ROTHMAN, R.N., MELE, A., REID, A.A., AKUNNE, H.C., GREIG, N., THURKAUF, A., DE COSTA, B.R., RICE, K.C. & PERT, A. (1991). GBR 12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol. Biochem. Behav., 40, 387397.
  • SABOL, K.E., LEW, R., RICHARDS, J.B., VOSMER, G.L. & SEIDEN, L.S. (1996). Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: synaptosomal uptake and tissue concentrations. J. Pharmacol. Exp. Ther., 276, 846854.
  • SABOL, K.E. & SEIDEN, L.S. (1998). Reserpine attenuated D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis. Brain Res., 806, 6978.
  • SANCHEZ, V., CAMARERO, J., ESTEBAN, B., PETERS, M.J., GREEN, A.R. & COLADO, M.I. (2001). The mechanisms involved in the long lasting neuroprotective effect of fluoxetine against MDMA (‘ecstasy’)-induced degeneration of 5-HT nerve endings in rat brain. Br. J. Pharmacol., 134, 4657.
  • SCHMIDT, C.J. & GIBB, J.W. (1985a). Role of the dopamine uptake carrier in the neurochemical response to methamphetamine: effects of amfonelic acid. Eur. J. Pharmacol., 108, 7380.
  • SCHMIDT, C.J. & GIBB, J.W. (1985b). Role of the serotonin uptake carrier in the neurochemical response to methamphetamine: effects of citalopram and chlorimipramine. Neurochem. Res., 10, 637648.
  • SCHMIDT, C.J., BLACK, C.K., ABBATE, G.M. & TAYLOR, V.L. (1990). MDMA-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res., 529, 8590.
  • SCHMIDT, C.J., FADAYEL, G.M., SULLIVAN, C.K. & TAYLOR, V.L. (1992). 5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur. J. Pharmacol., 223, 6574.
  • SCHMIDT, C.J., LEVIN, J.A. & LOVENBERG, W. (1987). In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem. Pharmacol., 36, 747755.
  • SCHMIDT, C.J., WU, L. & LOVENBERG, W. (1986). Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. Eur. J. Pharmacol., 124, 175178.
  • SCREATON, G.R., SINGER, M., CAIRNS, H.S., THRASHER, A., SARNER, M. & COHEN, S.L. (1992). Hyperpyrexia and rhabdomyolysis after MDMA (‘Ecstasy’) abuse. Lancet, 339, 677678.
  • SHANKARAN, M. & GUDELSKY, G.A. (1999). A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacology, 147, 6672.
  • STEPHENS, S.E. & YAMAMOTO, B.K. (1994). Methamphetamine-induced neurotoxicity. Roles for glutamate and dopamine efflux. Synapse, 17, 203209.
  • STONE, D.M., MERCHANT, K.M., HANSON, G.R. & GIBB, J.W. (1987). Immediate and long term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology, 26, 16771683.
  • STONE, D.M., STAHL, D.C., HANSON, G.R. & GIBB, J.W. (1986). The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur. J. Pharmacol., 128, 4148.
  • TEHAN, B. (1993). Ecstasy and dantrolene. Br. Med. J., 306, 146.
  • YAMAMOTO, B.K. & SPANOS, L.J. (1988). The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur. J. Pharmacol., 140, 195203.
  • YAMAWAKI, S., LAI, H. & HORITA, A. (1983). Dopaminergic and serotonergic mechanisms of thermoregulation: mediation of thermal effects of apomorphine and dopamine. J. Pharmacol. Exp. Ther., 227, 383388.